drugset / Trial / NCT06004947
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.
Timeline
- Start
- 2016-01-14
- Primary completion
- 2016-03-15
- Completion
- 2016-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avacopan | Small molecule | 30 mg | Oral |
| Subject | Celecoxib | Other / unclassified | 200 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Midazolam | Small molecule | 2 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |